



# Knockout Stable Cell Lines

## Product Manual





## Knockout Stable Cell Lines Product Information

### 1. Description

The knockout stable cell line uses genetic engineering technology to induce loss-of-function mutations at the target gene in mammalian cells. It is a key tool for exploring protein function, analyzing the effects of gene loss, and studying disease models.

With our customized service, you can get our high-quality customer service experience. The knockout stable cell line is an important research tool for target gene function discovery and research (e.g., signaling pathway research), target validation, antibody research, constructing models, drug screening and assay development. Researchers can study the effect of gene knockout on cells and verify the specificity of the target antibody.

### 2. Knockout Stable Cell Line Generation Service

Service	Technical method	Gene expression evaluation	Application	Delivery
Knockout Stable Cell Line Generation	CRISPR/Cas9	Sequence	Gene function research Protein engineering Recombinant antibodies development Drug discovery	Monoclonal cell line

### 3. Technical advantages



We have optimized and upgraded the CRISPR/Cas9 technology and developed a more efficient gene editing system, which can realize multiple knockout strategies such as frameshift knockout, fragment knockout, and multiple gene knockout of host cell genes. We have a lot of experience in constructing knockout stable cell lines, including but not limited to A549, CHO, HepG2 and other cell lines. In addition, we provide services such as cellular gene expression regulation and cell function verification. Finally, professional laboratory reports and quality inspection reports will be delivered.

**AcceGen Biotech**

277 Fairfield Road,  
Fairfield, NJ 07004, USA

T: [+1-862-686-2696](tel:+1-862-686-2696) | E: [inquiry@accegen.com](mailto:inquiry@accegen.com)  
F: [+1-323-978-5598](tel:+1-323-978-5598) | Homepage: [www.accegen.com](http://www.accegen.com)

## 4. Experimental process



## 5. Application Operations and Detection Methods

### Target gene function discovery and research

- Construct a gene knockout stable cell line
- Culture and expand the knockout stable cell line with the suitable medium and serum
- Group cells according to experimental requirements
- Study the effect of gene knockout on cells through various experimental methods in terms of phenotype or gene function.

**Western blotting** Cells were lysed using RIPA or other reagents, and the cell supernatant can be taken after centrifugation to determine the concentration of the target protein. Then the difference in protein expression between knockout cells and control cells can be obtained.

**RT-PCR** The process of extracting cellular RNA can be operated according to the nucleic acid extraction kit, and the target gene product can be obtained after reverse transcription and PCR amplification. Detect and observe the expression results of the target genes by agarose gel electrophoresis and gel imaging system.

**Flow Cytometry** Inoculate cells ( $5 \times 10^5$  cells/ml) into 6-well plates and culture them for 24 hours. Add antibodies or stimulating factors required for the experiment to the cells and incubate for several hours. Finally, a flow cytometer can be used to detect cell cycle and apoptosis, etc.

**AcceGen Biotech**  
277 Fairfield Road,  
Fairfield, NJ 07004, USA

T: [+1-862-686-2696](tel:+1-862-686-2696) | E: [inquiry@accegen.com](mailto:inquiry@accegen.com)  
F: [+1-323-978-5598](tel:+1-323-978-5598) | Homepage: [www.accegen.com](http://www.accegen.com)



**Statistical analysis** Experimental data can be analyzed using software such as SPSS, GraphPad Prism, Flow Jo, and Excel.

## 6. Delivery of Cell Lines and Report

1 vial of stable cell line ( $1 \times 10^6$  cells/vial) and sequencing report will be delivered to the customer. If the project requires the customer to provide a host cell, we will request the customer to fill in [AcceGen Custom Stable Cell Line Service Requisition Form](#).

## 7. Experimental case

### Case1: HEK293-hERRA-Knockout Cell Line

1. Design and synthesize gRNA
2. Plasmid vector construction

tccatggcaacagctaggagggacgftgctcgggacgctctctggaactgcggccctctcccccactgctgaggctggaagcctggccctaggcccgaggt  
 tgggcaaccgctgtagaggctgctccaccctccaccagctgcttgggaaagatgaggtggatgagcagcgcctgctcagccagcctgctcagccag  
 GTGGTGGGCGATTGAGCCTCTCTACATCAAGGCAGAGCCGGCCAGCCTGACAGTCCAAAGGGTCTCT  
 CGGAAGAGAGAGCAGAGCTCTCTGTGTTCCCTGGCCCTGGTCAGCTCCCACTCGTGCCTCCAGGC  
 CACAAGGAAGAGGAGATGGGAGGGGGCTGGCCCTGGCAGCAGGGCGGTGGGAAGCTGGTGTCT  
 AGCTCCCTGCCAAGGCCTCTGCTGCTGTGGGGACGTGGCTCCGGCTACCACATATGGTGTGGC

ERRA-gRNA1: GGAGAGACCCATAGGTTCCGAGG (gRNA1 10 Guide 95)  
 ERRA-gRNA2: AGGAACCCCTTTGGACTGTGACGGG (gRNA2 107 Guide 83)  
 ERRA-gRNA3: GACAGAGACCCGAGCCTCCTGTGG (gRNA3 154 Guide 66)

Fig.1a gRNA




Fig.1b Plasmid

3. Plasmid vector transfection into cells
4. Positive stable cells generation




Fig.1c Electroporation results

5. Validation results (PCR and Sequencing) Identification for positive clone




Fig.1d PCR results




Fig.1e Sequencing results

6. Positive monoclonal cells expansion
7. Cell cryopreservation and reports delivery

**AcceGen Biotech**  
 277 Fairfield Road,  
 Fairfield, NJ 07004, USA

T: +1-862-686-2696 | E: [inquiry@accegen.com](mailto:inquiry@accegen.com)  
 F: +1-323-978-5598 | Homepage: [www.accegen.com](http://www.accegen.com)



## Case2: HEK293-hERRG-Knockout Cell Line

### 1. Design and synthesize gRNA

### 2. Plasmid vector construction

aaatatacctatgagccataattggaatattagcgtttatgaggaattgattgttttcaaacacaaaatgctctagggttataaagagg  
atgatacctagtgatctgtagtgcctgctgctgcagataacaagattgctccattttgggctgaacggagaagatcagcc^T  
GCCTGACCCTACTGT...TCACTACACTGTG...TGACTTGGCCAGCCG  
AGAGTTGGTGGTTATCATTGGATGGCGAAGCATATTCCA...gtacattttcgtaaaagaaaaagaaaaggggt  
gcaataatccctaggttatglatagattgggtgaattcaaattttcattagactaaaaaacoccttacatttttaacataattagagttt  
gcatacctaagaatccttagactttat

ERRG-gRNA1: ACATTTGTTGGCTGAACCGG (gRNA1 46 Guide 76)

ERRG-gRNA2: GGGCTTGA/GTCACTGTGGGG (gRNA2 80 Guide 88)

ERRG-gRNA3: TGACTTGGCCAGCGAGAGTGG (gRNA3 136 Guide 98)

Fig.2a gRNA




Fig.2b Plasmid

### 3. Plasmid vector transfection into cells

### 4. Positive stable cells generation




Fig.2c Electroporation results

### 5. Validation results (PCR and Sequencing) Identification for positive clone




Fig.2d PCR results

Translate	Consensus	GACGAAACACCGGACATTTGGTGGCTGAACGTTTATGAGCTAGAAAATAGC
g1907124598-ERRG-1-3_U6-5.ab1 (1>653)		GACGAAACACCGGACATTTGGTGGCTGAACGTTTATGAGCTAGAAAATAGC
221466-gRNA1.seq (1>20)		ACATTTGTTGGCTGAAC
Position: 1		

Translate	Consensus	GGACGAAACACCGGGCTTTGATGTCAGCTGTCGGTTTATGAGCTAGAAAATAGC
g1907124600-ERRG-2-4_U6-5.ab1 (1>651)		GGACGAAACACCGGGCTTTGATGTCAGCTGTCGGTTTATGAGCTAGAAAATAGC
221466-gRNA2.seq (1>20)		TGGCTTGA/GTCACTGTGG
Position: 1		

Translate	Consensus	ACGAAACACCGTACTTGGCCAGCGAGAGTGTATGAGCTAGAAAATAGC
g1907124602-ERRG-3-2_U6-5.ab1 (1>652)		ACGAAACACCGTACTTGGCCAGCGAGAGTGTATGAGCTAGAAAATAGC
221466-gRNA3.seq (1>20)		TGACTTGGCCAGCGAGAGT
Position: 1		

Translate	Consensus	CTTCTGCACTCTG
221466-gRNA1.seq (1>467)		CTTCTGCACTCTG
g1907124601-ERRG-1-2_U6-5.ab1 (1>248)		CTTCTGCACTCTG
g1907124602-ERRG-3-2_U6-5.ab1 (1>251)		CTTCTGCACTCTG
Position: 1		

Fig.2e Sequencing results

### 6. Positive monoclonal cells expansion

### 7. Cell cryopreservation and reports delivery

AcceGen Biotech

277 Fairfield Road,  
Fairfield, NJ 07004, USA

T: [+1-862-686-2696](tel:+18626862696) | E: [inquiry@accegen.com](mailto:inquiry@accegen.com)

F: [+1-323-978-5598](tel:+13239785598) | Homepage: [www.accegen.com](http://www.accegen.com)

### Case3: 293T-hCRBN-Knockout Cell Line

- Design and synthesize gRNA
- Plasmid vector construction

**gRNA Sequence**

```

GGAGGTTGGGGGGGTCTGATACCAATGTAAAGTSSBATTCCGAAACGCAAAAAGACTAGATAAAGACTAAGGAACTCATTGAAATATGAAAGCTTAATTGAGATAGTGTACGAGAGACTGATCTGCTGTGTGTGGCAATGTACGATACATATATAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
CCCTCCGACCCCTGAGATTATGATTACATATCCGACCTAGACCTTGAGTTTTCTGCTATTGTTGCTTCCCTAAGTAAATTTTATACCTGGATCAATCTCATACGATGATCTGACTAGAGAGAACAGCGCTTACATGATGATATATTTT
TTAACATTAGGGGAAAAAGATATGTACACAGCGGGAGACTTCTGTACTATCTTTACACCTTCTCTGTAAATTTTAACTATCTTAAGATTCACAGTTTCACTTAAAGTTCCACGTTTCACTTAAGAAATAAAATAAAATATGAGTCTCCTC
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAATTATATCCCCCTTCTCAGACACTGTGTCCCTCTAAGACATGATAGAAATTTGAAAGACATTTGACAAATTGATAAGATTTTAAAGTGTCACTGAAATTTTTTTTTTATGCGATCACTGCTCGGGTCTGCCCTGGGTCAAGACCGCAGGAA
TTACAGTTCTGTAGAGTTTACCAAAATGATGTGTTTTAAAGATCCCTCCTTTTAAAGAAATATGATGTTTTAAAGGTTTTTATGATCTCTTTTCTTTTTCATCAATATCTGATTTTATAGCAGAGATGAGGAAAGATGAAATGAAATTT
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAGTCTGACAGCTCTCAAAATGATTTACATAGCAGCAAAATCTCATGGGAAAGAACTCTCTCTCTTAAATGACAAACTTCCAAAGATAAGTAAGAAAAAAAAGAAATGTTATAGAAATGAAATAGTCTGTGACGCTCTCTCACTTCACTCTCA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
GAAATCATAGATATGTAAGGAGGCAAAAAGCAAGACATCTCAAAATTTGACACCGCTCTCCGACATGACATGATATGATTAATTTAAAGATCTGATAATGATGATGATTAAGTGTGATGAAAGTTTTGTAAGAAAGCAAGTGTATTGT
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
CTGTGATCTGATGTTTTCTGAGTTTTTGGTTTTTAAATGTTAGTATAGAGAGGTTAGTATATGATATTAATTAAGTACAGTCTAGATTAATATATATATATGAAATTTTAAAGTATTTGTCAGTGAATAGAG
TATTACTATATGAAAATTTGAAATAGAGAGCGAGTTATTTGGCAGTAAAGCACTTAACTGATTTTTTAAAGGTTTTGATCACTATGTTATGATGAGATTTTTGAGGATTTGCTCTGTATCTCTCTGTAATGAGGTATTAATAG
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
ATATATGATCTATAGTTTAAAGCACTCTCTGACAGGTAAAGGTTGATATATTGAAATGAGATTAAGAAATCTTGGAAATTAAGTAGAAGAGCACTTAAAGCACTCTTAAACAGCGAAGATATAGAAAGACATCACTCTGATTTATG
TTTTCTACTCTGAGTACTAGAGTTTATTGAACTACTAGATTTTATACCTGATGTTGTGGTATGTGGCATAAGATATTTCTGTAAATTAATCACTCTGATCAAAAATCTGAAATTTCTGTGTGTTTGTATATATTGATAAAAGATTA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAGAGACATGAAGGTGATGCTCCAGATACCTGTTATGTTAAATATGAAATGACAAACATACAGCGATCTCTATAGAAAGCAATTTTATTAAGACATGTTTTTAAAGACTTAAAGACAGCACTATGAAATTTTCTCAAT

```

Fig.3a gRNA

- Plasmid vector transfection into cells
- Positive stable cells generation
- Validation results (PCR and Sequencing) Identification for positive clone




Fig.3b PCR results

**Sanger Sequencing**



Fig.3c Sequencing results

- Positive monoclonal cells expansion
- Cell cryopreservation and reports delivery




Fig.3d Knockout cells



+1-862-686-2696  
277 Fairfield Road,  
Fairfield, New Jersey 07004, USA

[inquiry@accegen.com](mailto:inquiry@accegen.com)  
[www.accegen.com](http://www.accegen.com)